Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Journey Medical CorporationNASDAQ: DERM
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1.15M rose 5.8% year over year, behind the +16.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Depreciation & amortization amounted to 7.0% of revenue in FY2025, up 0.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +16.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.35M USD
- Year-over-year change
- +23.6%
- 4-year CAGR
- +14.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.35M | +23.6% |
| FY2024 | 2024-12-31 | 3.52M | -8.8% |
| FY2023 | 2023-12-31 | 3.86M | -11.7% |
| FY2022 | 2022-12-31 | 4.37M | +70.5% |
| FY2021 | 2021-12-31 | 2.56M | — |
Depreciation & Amortization vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.5% is the 5th highest of 10, against a peer median of +13.8%.
- Depreciation & amortization amounts to 6.8% of revenue for DERM, versus a peer median of 8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | $9.54M USD | +11.9% | -10.7% | 8.4% | |
| LTM Mar 2026 | €5.27M EUR | +149.9% | +32.4% | 32.3% | |
| LTM Mar 2026 | $4.39M USD | +16.5% | -0.1% | 6.8% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Mar 2026 | $2.42M USD | +13.8% | +13.3% | 136.2% | |
| LTM Mar 2026 | $1.88M USD | +27.6% | +13.5% | 13.0% | |
| LTM Mar 2026 | $672K USD | +1192.3% | +38.7% | 7.0% | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $103K USD | +0.0% | -11.6% | 0.2% | |
| Peer median (excluding DERM) | — | +13.8% | +13.6% | 8.4% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.